CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
CytomX Therapeutics (CTMX), a pioneer in masked, conditionally activated biologics, has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. Sean McCarthy, CEO and chairman, will engage in a fireside chat on December 4, 2024, at 8:00 a.m. ET. The presentation will be accessible via live webcast on CytomX's website. The company's management team will also be available for individual meetings with registered conference investors.
CytomX Therapeutics (CTMX), pioniere nella biologia attivata condizionatamente e mascherata, ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Sanità Piper Sandler. Sean McCarthy, CEO e presidente, parteciperà a una chiacchierata informale il 4 dicembre 2024 alle 8:00 a.m. ET. La presentazione sarà disponibile tramite webcast dal vivo sul sito web di CytomX. Anche il team di gestione dell'azienda sarà disponibile per incontri individuali con gli investitori registrati alla conferenza.
CytomX Therapeutics (CTMX), pionero en biológicos activados condicionalmente y enmascarados, ha anunciado su participación en la 36ª Conferencia Anual de Salud Piper Sandler. Sean McCarthy, CEO y presidente, participará en un chat informal el 4 de diciembre de 2024 a las 8:00 a.m. ET. La presentación estará disponible a través de una transmisión en vivo en el sitio web de CytomX. El equipo de gestión de la compañía también estará disponible para reuniones individuales con los inversores registrados en la conferencia.
사이톰엑스 테라퓨틱스 (CTMX)는 조건부로 활성화된 마스킹 생물학의 선구자로서 제36회 파이퍼 샌들러 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 션 맥카시 CEO 겸 회장이 2024년 12월 4일 오전 8시(동부 표준시)에 파이어사이드 채팅에 참여합니다. 발표는 CytomX 웹사이트를 통해 생중계로 시청할 수 있습니다. 회사의 경영진도 등록된 투자자와의 개별 미팅을 위해 대기하고 있습니다.
CytomX Therapeutics (CTMX), pionnier des biothérapies masquées et activées de manière conditionnelle, a annoncé sa participation à la 36ème Conférence Annuelle de Santé Piper Sandler. Sean McCarthy, PDG et président, participera à une discussion informelle le 4 décembre 2024 à 8h00 HAE. La présentation sera accessible par webdiffusion en direct sur le site de CytomX. L'équipe de direction de l'entreprise sera également disponible pour des réunions individuelles avec les investisseurs enregistrés à la conférence.
CytomX Therapeutics (CTMX), ein Pionier im Bereich von maskierten, bedingt aktivierten Biologika, hat seine Teilnahme an der 36. jährlichen Piper Sandler Healthcare Conference angekündigt. Sean McCarthy, CEO und Vorsitzender, wird am 4. Dezember 2024 um 8:00 Uhr ET an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Live-Stream auf der Website von CytomX zugänglich sein. Das Management-Team des Unternehmens steht auch für persönliche Gespräche mit registrierten Konferenzteilnehmern zur Verfügung.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024, at 8:00 a.m. ET.
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), T-cell engagers, and immune modulators such as cytokines. CytomX’s clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ
When is CytomX Therapeutics (CTMX) presenting at the Piper Sandler Healthcare Conference 2024?
How can investors watch CytomX Therapeutics' (CTMX) presentation at the Piper Sandler Conference?
Will CytomX Therapeutics (CTMX) management be available for investor meetings at the Piper Sandler Conference?
What type of presentation will CytomX Therapeutics (CTMX) give at the Piper Sandler Healthcare Conference?
